- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, June 30, 2023
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article by Healio referenced a study published online ahead of print in the October 2023 issue of The American Journal of Managed Care® (AJMC®). The study, “Choosing Wisely Interventions to Reduce Antibiotic Overuse in the Safety Net,” evaluated the effect of an intervention based on Choosing Wisely principles on prescribing antibiotics for viral respiratory tract infections in a real-world safety-net setting.
An article by HealthcareITNews referenced a contributor article published on AJMC.com, the website of AJMC. The article, “Violence Against Healthcare Workers: A Rising Epidemic,” featured an opinion piece on how more attention needs to be given to the increasing rate of violence against workers in the health care industry.
An article from Dermatology Times® referenced an article published on AJMC.com. The article, “Experts Herald ‘Year of the JAK Inhibitor’ in Dermatology,” covered a panel at the American Academy of Dermatology 2023 that featured speakers discussing current data on the use of Janus kinase (JAK) inhibitors in dermatology.
An article from The Western Journal referenced an article published on AJMC.com. The article, “NATALEE: Ribociclib With Hormonal Therapy Cuts Recurrence Risk by 25% in Most Common Type of Breast Cancer,” focused on a trial that included patients with earlier stage breast cancer normally considered lower risk.
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen
Oral GC Dose Tapering for MG Linked to Efgartigimod Initiation
August 25th 2025Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis: 3 months before starting efgartigimod and 3, 6, 9, and 12 months after starting efgartigimod.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
